Skip to main content
Image coming soon

GEN5073 Mastering High-Throughput Screening in Natural Product Validation

$199.00
Adding to cart… The item has been added

What is the High-Throughput Screening in Natural Product course about?

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which high-throughput screening methods to prioritize for validating natural compound efficacy. Each order is checked and updated against the latest insights before delivery. That is why access takes.

What does the High-Throughput Screening in Natural Product cover on the situation this is built for?

You are responsible for determining which natural compounds advance from hit identification to lead optimization. But today’s array of cell-based assays, phenotypic screens, target deconvolution tools, and multiplexed readouts creates decision paralysis. Each method promises speed and scalability, yet few deliver reproducible, mechanism-informed results. Without a clear evaluation framework, you risk backing assays that generate false positives, fail orthogonal validation, or don’t.

Who is the High-Throughput Screening in Natural Product course for?

Senior research lead in biological drug discovery overseeing natural product screening pipelines, responsible for assay strategy, resource allocation, and cross-functional alignment with pharmacology, DMPK, and translational medicine teams.

Who is the High-Throughput Screening in Natural Product course not for?

This is not for computational biologists building screening algorithms, procurement specialists evaluating instrument vendors, or early-career scientists learning basic assay techniques.

What do you take away from the High-Throughput Screening in Natural Product course?

Define a repeatable process for comparing screening modalities against program-specific success criteria Document technical and operational trade-offs between assay formats using standardized evaluation matrices Lead evidence-based discussions with stakeholders during compound nomination meetings Anticipate downstream attrition risks introduced by upstream screening choices Build institutional memory around why certain methods were selected or retired.

How does this map to your situation?

Current state assessment of screening operations Evaluation of technological and methodological alternatives Stakeholder alignment and decision governance Long-term capability building and knowledge retention.

What's included with your purchase?

12 modules with 12 chapters each (144 chapters) Downloadable templates and worked examples for every module Hand-built implementation playbook delivered alongside course access 30-day money-back guarantee.

What does the High-Throughput Screening in Natural Product cover on delivery and format?

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access. Time investment: Approximately 3 hours per module, designed to be completed over 12 weeks with practical application between units.

More answers: what you get with every course, refund policy, all help answers.

The Executive Diagnostic and Governance Toolkit

Mastering High-Throughput Screening in Natural Product Validation

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which high-throughput screening methods to prioritize for validating natural compound efficacy.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Choosing the wrong high-throughput screening path wastes months of work and misdirects critical resources.

The situation this is built for

You are responsible for determining which natural compounds advance from hit identification to lead optimization. But today’s array of cell-based assays, phenotypic screens, target deconvolution tools, and multiplexed readouts creates decision paralysis. Each method promises speed and scalability, yet few deliver reproducible, mechanism-informed results. Without a clear evaluation framework, you risk backing assays that generate false positives, fail orthogonal validation, or don’t translate across model systems. The cost isn't just time—it's lost credibility with development teams and executive sponsors who demand defensible progression criteria.

Who this is for

Senior research lead in biological drug discovery overseeing natural product screening pipelines, responsible for assay strategy, resource allocation, and cross-functional alignment with pharmacology, DMPK, and translational medicine teams.

Who this is not for

This is not for computational biologists building screening algorithms, procurement specialists evaluating instrument vendors, or early-career scientists learning basic assay techniques.

What you walk away with

  • Define a repeatable process for comparing screening modalities against program-specific success criteria
  • Document technical and operational trade-offs between assay formats using standardized evaluation matrices
  • Lead evidence-based discussions with stakeholders during compound nomination meetings
  • Anticipate downstream attrition risks introduced by upstream screening choices
  • Build institutional memory around why certain methods were selected or retired

How this maps to your situation

  • Current state assessment of screening operations
  • Evaluation of technological and methodological alternatives
  • Stakeholder alignment and decision governance
  • Long-term capability building and knowledge retention

Before vs. after

Before
Uncertain which screening investments will yield translatable results, struggling to justify method choices to leadership, and reacting to artifacts instead of preventing them.
After
Confidently selecting and defending screening strategies based on documented evaluation criteria, with stakeholder-aligned processes and institutional knowledge infrastructure in place.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 3 hours per module, designed to be completed over 12 weeks with practical application between units.

If nothing changes
Continuing without a formal evaluation framework means repeated investment in underperforming assays, increased late-stage failures due to poor early data quality, and diminished influence in portfolio decision meetings.

How this compares to the alternatives

Unlike generic laboratory technique guides or vendor-sponsored webinars, this course focuses exclusively on the strategic decision-making required to own and evolve a natural product screening function within a modern discovery organization.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Foundations of Efficacy Assessment in Natural Product Discovery
Establish core principles for evaluating biological activity in complex extracts and purified isolates.
12 chapters in this module
  1. Understanding the difference between bioactivity and therapeutic efficacy
  2. Mapping chemical complexity to assay design challenges in natural products
  3. Defining minimum acceptable evidence for target engagement claims
  4. Evaluating matrix effects from crude extracts in primary screens
  5. Setting thresholds for dose-response consistency in replicate testing
  6. Integrating counter-screen data to rule out nonspecific effects
  7. Assessing interference from flavonoids, tannins, and redox-active moieties
  8. Designing stability controls for labile natural compounds
  9. Interpreting cytotoxicity data in context of desired pharmacology
  10. Balancing sensitivity and specificity in low-abundance compound detection
  11. Documenting batch-to-batch variability in plant-derived samples
  12. Creating traceability from source material to final assay result
Module 2. Evaluating Assay Technologies for Throughput and Relevance
Compare platform capabilities beyond vendor specifications using real-world performance metrics.
12 chapters in this module
  1. Benchmarking fluorescence-based readouts against label-free alternatives
  2. Assessing dynamic range limitations in luminescent reporter systems
  3. Validating impedance-based assays for adherent cell models
  4. Testing compatibility of mass spectrometry detection with live-cell workflows
  5. Measuring edge effects in 1536-well plate screening campaigns
  6. Quantifying evaporation artifacts in extended-duration assays
  7. Evaluating cell health markers during prolonged incubation periods
  8. Comparing single-endpoint versus kinetic measurement strategies
  9. Determining optimal seeding density for phenotypic screening
  10. Monitoring mycoplasma contamination impact on assay variability
  11. Calibrating automated liquid handlers for viscous natural product solutions
  12. Assessing carryover risk in serial dilution workflows
Module 3. Designing Tiered Screening Cascades for Natural Compounds
Structure sequential validation steps that filter artifacts while preserving mechanistic insight.
12 chapters in this module
  1. Defining go/no-go criteria between primary and secondary assays
  2. Incorporating orthogonal assays to confirm on-target activity
  3. Sequencing functional assays ahead of binding affinity measurements
  4. Including solubility profiling early in the cascade
  5. Using thermal shift assays as triage tools for direct binders
  6. Implementing cytotoxicity counterscreens at multiple stages
  7. Integrating metabolic stability assessments pre-hit confirmation
  8. Adding efflux transporter interference checks in cellular models
  9. Scheduling microsomal stability tests before animal dosing
  10. Placing hERG liability screening ahead of chronic toxicity models
  11. Embedding off-target panel testing after initial efficacy readouts
  12. Timing pharmacokinetic sampling relative to pharmacodynamic endpoints
Module 4. Managing False Positives and Artifacts in Natural Product Screening
Systematically identify and eliminate misleading signals arising from compound properties.
12 chapters in this module
  1. Detecting aggregation-based inhibition in enzyme assays
  2. Identifying redox cycling compounds using catalase controls
  3. Screening for thiol-reactive molecules with glutathione adducts
  4. Recognizing chelator interference in metalloenzyme studies
  5. Filtering autofluorescent compounds from imaging datasets
  6. Accounting for light scattering in turbid sample matrices
  7. Controlling for solvent precipitation in DMSO stocks
  8. Tracking degradation products via LC-MS during incubation
  9. Flagging promiscuous inhibitors using negative control profiles
  10. Monitoring pH shifts from organic acid contaminants
  11. Assessing membrane disruption using dye leakage assays
  12. Validating activity retention after size-exclusion chromatography
Module 5. Data Quality and Reproducibility in High-Throughput Workflows
Instill rigorous quality standards across all stages of screening execution.
12 chapters in this module
  1. Calculating Z-prime factors for every plate-based assay run
  2. Setting acceptable limits for positive control response variation
  3. Implementing interplate normalization using reference standards
  4. Tracking intra-assay coefficient of variation over time
  5. Auditing raw data files for evidence of manual manipulation
  6. Requiring full metadata capture for every screening campaign
  7. Enforcing timestamped electronic lab notebook entries
  8. Verifying instrument calibration logs before data acceptance
  9. Applying batch correction methods to multi-day runs
  10. Conducting retrospective power analysis on low-magnitude hits
  11. Archiving raw .tiff and .csv files with chain-of-custody logs
  12. Performing blinded retesting of borderline active compounds
Module 6. Cross-Functional Alignment on Screening Strategy Decisions
Facilitate productive dialogue between discovery biology, chemistry, and translational teams.
12 chapters in this module
  1. Presenting assay limitations clearly during project team meetings
  2. Translating technical variability into portfolio risk statements
  3. Aligning on minimum effect size required for progression
  4. Negotiating acceptable false discovery rates with stakeholders
  5. Clarifying expectations around reproducibility across labs
  6. Integrating medicinal chemistry input during hit triage
  7. Incorporating DMPK feedback into early permeability screening
  8. Soliciting toxicology perspectives on structural alerts
  9. Co-developing decision trees with pharmacokinetics experts
  10. Sharing validation failure postmortems across programs
  11. Standardizing terminology across departments for assay outcomes
  12. Establishing joint review gates for advancing natural product leads
Module 7. Target Deconvolution Strategies Following Phenotypic Hits
Navigate from observed phenotype to molecular mechanism with confidence.
12 chapters in this module
  1. Prioritizing hits with clean cytotoxicity profiles for deconvolution
  2. Using chemoproteomics to pull down bound proteins from cell lysates
  3. Applying CRISPR knockout screens to validate genetic dependencies
  4. Conducting thermal proteome profiling across concentration gradients
  5. Leveraging gene expression signatures to infer pathway modulation
  6. Testing rescue phenotypes with exogenous substrate addition
  7. Mapping structure-activity relationships across analog series
  8. Correlating potency shifts with known target inhibitors
  9. Employing photoaffinity labeling for covalent binder identification
  10. Utilizing metabolomics to detect pathway-level perturbations
  11. Assessing target specificity using isogenic cell line panels
  12. Validating binding kinetics with surface plasmon resonance
Module 8. Integrating Multi-Omics Data into Screening Interpretation
Use transcriptomic, proteomic, and metabolomic datasets to enrich hit understanding.
12 chapters in this module
  1. Aligning RNA-seq clusters with known disease signatures
  2. Filtering hits that induce stress response gene programs
  3. Detecting unintended immune activation in transcript profiles
  4. Mapping proteomic changes to druggable protein families
  5. Identifying compensatory pathways in adaptive resistance models
  6. Correlating metabolite flux alterations with phenotypic outcomes
  7. Using pathway enrichment analysis to support mechanism claims
  8. Differentiating direct from indirect target modulation patterns
  9. Integrating phosphoproteomics to locate signaling nodes
  10. Assessing on-target engagement using occupancy biomarkers
  11. Comparing omics responses across species for translatability
  12. Storing normalized omics data in searchable internal repositories
Module 9. Resource Allocation and Capacity Planning for Screening Campaigns
Optimize use of personnel, instrumentation, and compound inventory under constraints.
12 chapters in this module
  1. Forecasting plate consumption for full cascade completion
  2. Estimating full-time equivalent needs for data review cycles
  3. Prioritizing campaigns based on therapeutic area urgency
  4. Allocating cryopreserved cell stocks across concurrent projects
  5. Scheduling access to shared high-content imaging systems
  6. Balancing staff workload during peak screening seasons
  7. Budgeting for confirmatory assay reagents and controls
  8. Reserving automation time for large-scale dilution series
  9. Managing vial inventory for rare or low-yield natural isolates
  10. Planning staggered start dates to avoid data bottlenecks
  11. Assigning backup analysts for critical path experiments
  12. Tracking equipment downtime in throughput projections
Module 10. Regulatory Considerations in Preclinical Natural Product Development
Anticipate agency expectations for data package completeness and traceability.
12 chapters in this module
  1. Ensuring botanical identification follows herbarium voucher standards
  2. Documenting collection location and environmental conditions
  3. Providing detailed extraction and fractionation procedures
  4. Reporting compound purity with multiple analytical methods
  5. Characterizing major impurities and their biological activity
  6. Demonstrating consistent activity across production batches
  7. Justifying choice of animal models for traditional medicine claims
  8. Addressing xenobiotic metabolism differences in study design
  9. Preparing CMC sections with natural product-specific details
  10. Handling stereochemistry disclosures for chiral natural compounds
  11. Meeting ICH guidelines for genotoxicity screening thresholds
  12. Submitting stability data appropriate for complex mixtures
Module 11. Decision Frameworks for Advancing or Terminating Screening Paths
Apply structured logic to retire unpromising approaches and double down on validated ones.
12 chapters in this module
  1. Creating weighted scoring systems for assay performance comparison
  2. Using decision logs to record rationale for platform adoption
  3. Conducting retrospective reviews of abandoned screening initiatives
  4. Applying failure mode analysis to recurring artifact problems
  5. Setting predefined exit criteria for underperforming technologies
  6. Benchmarking internal success rates against historical benchmarks
  7. Evaluating cost per actionable result across methods
  8. Assessing team proficiency growth curves for new platforms
  9. Measuring time saved in downstream validation phases
  10. Tracking reduction in late-stage attrition due to better screening
  11. Updating frameworks annually based on portfolio outcomes
  12. Sharing decision rules across therapeutic area teams
Module 12. Building Institutional Knowledge Around Screening Excellence
Create lasting infrastructure that outlives individual projects and personnel.
12 chapters in this module
  1. Developing internal training modules for new screening staff
  2. Curating a library of failed assay attempts and lessons learned
  3. Standardizing data formats across discovery programs
  4. Implementing centralized databases for screening results
  5. Creating templates for cross-project meta-analyses
  6. Hosting quarterly assay science roundtable discussions
  7. Publishing internal white papers on best practices
  8. Archiving deprecated protocols with retirement justifications
  9. Maintaining an annotated inventory of available cell models
  10. Cataloging known problematic compounds and their behaviors
  11. Establishing mentorship pairings for junior scientists
  12. Linking screening decisions to eventual clinical outcomes

Frequently asked

Is this course focused on small molecules or biologics?
The course centers on natural products, which include small molecule secondary metabolites from plants, microbes, and marine organisms, with applicability to both synthetic derivatives and purified isolates.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Will I learn how to operate specific instruments?
No. This course does not cover instrument operation manuals or protocol execution; it focuses on strategic assessment of which methods to adopt, adapt, or retire.
Can I share the materials with my team?
Each enrollment is licensed to one individual. Team licensing is available upon request through enterprise arrangements.
Does the course include live sessions or coaching calls?
No. The course is self-paced and text-based, with no scheduled calls or group events included in the standard offering.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 3 hours per module, designed to be completed over 12 weeks with practical application between units..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!